Vanshylla, Kanika

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Gruell, H., Vanshylla, K., Tober-Lau, P., Hillus, D., Schommers, P., Lehmann, C., Kurth, F., Sander, L. E., & Klein, F. (2022) · Nature Medicine

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 410

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans

Vanshylla, K., Di Cristanziano, V., Kleipass, F., Dewald, F., Schommers, P., Gieselmann, L., Gruell, H., Schlotz, M., Ercanoglu, M. S., Stumpf, R., et al. (2021) · Cell Host & Microbe

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 153

Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers

Tober-Lau, P., Schwarz, T., Vanshylla, K., Hillus, D., Gruell, H., EICOV/COVIM Study Group, Suttorp, N., Landgraf, I., Kappert, K., Seybold, J., et al. (2021) · The Lancet Respiratory Medicine

SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

Cited by 69

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Kreer, C., Zehner, M., Weber, T., Ercanoglu, M. S., Gieselmann, L., Rohde, C., Halwe, S., Korenkov, M., Schommers, P., Vanshylla, K., et al. (2020) · Cell

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 67